Skip to main content

IMPORTANCIA DEL INFLAMASOMA EN LA SENSIBILIDAD O RESISTENCIA A INHIBIDORES TIROSINA QUINASA EN PACIENTES CON CANCER DE HIGADO

PI18/00358

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Trial, Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Matilla, Ana
  • Lledó-Navarro, José Luis|||0000-0001-7973-3503
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Iñarrairaegui, Mercedes|||0000-0001-9180-4693
  • Perelló, Christie|||0000-0003-0234-2330
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Llarch, Neus|||0000-0003-3209-0453
  • Márquez, Laura
  • Guerrero, Antonio
  • Iserte, Gemma|||0000-0003-3908-8743
  • Castaño-García, Andrés|||0000-0002-7921-9026
  • Carrión, Laura
  • Fortuny, Marta
  • Rimola, Jordi|||0000-0002-1814-4198
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Domenech, Gema
  • Torres, Ferran|||0000-0002-7355-7913
  • Ríos, José|||0000-0002-0716-8784
  • Boix, Loreto|||0000-0002-6015-3901
  • Samper, Esther
  • Kateb, Àngels
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

  • Corominas Argente del Castillo, Josep|||0000-0002-5351-9469
  • Sapena, Victor|||0000-0003-4379-6486
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Millán, Cristina
  • Samper, Esther
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Torres, Ferran|||0000-0002-7355-7913
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Boix, Loreto|||0000-0002-6015-3901
  • Reig, María|||0000-0002-5711-9534
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.